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ABSTRACT 
Objective: This study was conducted to explore the expression levels of HTR1A gene in a sample of Egyptian autistic children.  
Methods: Thirty autistic patients (18 boys, 12 girls) and 20 controls were enrolled in the study. From each child, we isolated RNA samples from 
whole blood. Quantitative Real-Time PCR (qRT-PCR) was used to measure the gene expressions of HTR1A and normalized to the housekeeping 
gene, beta-actin.  
Results: The HTR1A gene expression of healthy controls and ASD subjects were varied significantly (p =0.0062). As compared to control of healthy 
subjects, the HTR1A expressions were greatly reduced in samples of ASD.  
Conclusion: HTR1A gene expression level is a candidate gene for further studies to explore its potential roles in ASD related pathways. 
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It is well established that a complex interaction between genetic, 
epigenetic and environmental factors derives Autism’s etiology. 
Chromosomal rearrangements at almost all chromosomes have been 
noticed among individuals with autism spectrum disorder (ASD) [1]. 
Unfortunately, little is known about the genetic variants and their 
contribution to the development of the ASD disorder. However, 
studying autistic related symptomatology may add to our knowledge 
about related genes and may help to further understanding of these 
disorders. For example, many serotonin polymorphisms were 
correlated with the level of IQ [2]. 
Various biological processes, besides, variations in gene expression 
levels between different biological tissues are implicated with ASD 
individuals. Moreover, some studies utilize gene expression analysis 
pattern to categorize autism into different subcategories. A list of 
genes found to be significantly dysregulated in ASD is needed to help 
further researchers to define any abnormalities useful for diagnosis 
or treatment [3].  
The gene coding the 5-HT1A receptor is 1.27kb and intronless. It is 
located on the long arm of chromosome 5. The family of G protein-
coupled receptors (GPCRs) includes serotonin 1A receptors which 
are involved in behavior, development and cognition [4]. 
Consequently, the serotonin 1A receptor serves as an important 
target for neuropsychiatric disorders; for example; anxiety, 
depression and neuronal developmental defects [5].  
High levels of serotonin in platelet were the first observation to relate 5-
HT to ASD [6, 7]. In 25-50% of ASD patients, hyperferritinemia was 
observed [6]. In the prefrontal cortex, high concentrations of serotonin 
1A receptors are distributed. Due to its ability to reverse drug-induced 
cognitive deficits, HT1A receptor antagonists may be a good tool to cure 
age-related cognitive impairment [8]. The serotonin 5HT1A receptor has 
gained extensive investigations on their role in development, plasticity, 
and memory processes in the human brain [9]. 
HTR1A receptors are found as an auto receptor in the soma and 
dentrities of serotonergic neurons. And hence, reduction of the 
HTR1A autoreceptor activity results in an increase in serotonin 
transmission, suppress the function of target neurons mediated by 
HTR1A and results in a reduction in the potency of neural 
transmission [10]. Many transcriptional regulators of the 5-HT1A 
receptor have been identified [11].  
The serotonin 1A receptor, as well as, serotonin neurotransmitter 
system was extensively involved in the pathophysiology of mood 
and anxiety disorders. However, the researchers found that there is 
a variation in the genetic correlations [12]. Gross et al. [13] found 
that a varied pattern of up-regulated fear-related behaviors was 
showed by knock-out 5-HT1A receptor in mice. 
Gene expression studies are helpful in the comparison between 
groups of subjects with ASD and healthy control samples in order to 
elucidate genes that are interrupted in the ASD group. And hence, 
this study was carried out to investigate HTR1A gene expression 
levels in ASD children. This also will be useful in increasing our 
knowledge about understanding autism development. Moreover, 
this will help in tailoring treatment strategies targeting the 
serotonergic system in the near future.  
MATERIALS AND METHODS 
Patient selection  
This study was carried out on 30 children with autism (group I), 
their ages ranges between 6-13 y receiving care at Neuro-
Rehabilitation Clinic, Center of Excellence of Medical Research, 
Department of Research on Children with Special Needs, Medical 
Division- National Research Centre. Group II included 20 normal 
children matched for age, sex and socioeconomic status with group I. 
The study was approved by the ethical committee of Medical 
research division, National Research Centre, approval number 18-
173. An informed consent was taken from each child's guardian.  
The inclusion criteria 
Diagnosed cases using 3 psychometric assessments; Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV), Childhood Autism Rating Scale (CARS) and Autism Diagnostic 
Interview-Revised (ADI-R). Their age range between 6-13 y, 
Exclusion criteria  
Cases received vitamins 3 mo before the study; Cases with auditory, 
vestibular, visual and respiratory defects; Cases with identified 
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metabolic, genetic, or progressive neurological disorders, based on 
screening by clinical staff; and Secondary autistics with Genetic/ 
Medical conditions. 
Quantitative real-time gene expression analysis  
This was done using SensiFast®
Statistical analysis 
 syberGreen one-step RT-PCR 
(Bioline). Briefly, total RNA was extracted from peripheral blood 
cells after RBC’s lysis using Qiazole lysis reagent (Qiagen, USA) 
according to the manufacturer instructions. Primer sequence for β-
actin gene is: Forward, CCTTCCTGGGCATGGAGTCCT; Reverse, 
GGAGCAATGATCTTGATCTTC; for HTR1A: Forward, GGCAACA-
ACACCACATCACC, Reverse, and GACGGTCACGTCGGAGATAC. The 
copy numbers were normalized to 100,000 copies of the 
housekeeping beta-actin gene. The RT and subsequent PCR cycling 
conditions were as follows: 50 °C for 10 min, 95 °C for 5 min, 60 °C 
for 30 s and then 95 °C for 15 s; the number of cycles were 40 cycles. 
BioRad Miniopticon™ real-time PCR cycler was used for quantitative 
estimation.  
The data were analyzed using Microsoft Excel. All the data are 
expressed as mean±standard error mean. Analysis of the data was 
done using student t-test to detect the significant difference between 
the studied groups. A level of P<0.05 was defined as statistically 
significant. Data are represented as mean±sem. 
RESULTS 
In the study subjects, there were 18 males and 12 females ADS 
patients, besides, 10 females and 10 males' healthy controls. The 
average age ranged between 9.0±0.33 in the patient group and 
9.1±1.4 in the control group. No significant differences were 
recorded between the groups for Gender (P=0.3, 0.92 for ADS 
patients and control, respectively) or age (P=0.98). HTR1A gene 
expression levels were normalized to 100000 copies of beta-actin. 
We found a high significant difference (p = 0.0062) in HTR1A gene 
expression between children suffering from ASD and healthy 
children group (table 1). 
 
Table 1: The expression levels of HTR1A gene and demographic features of ADS patients and control group 
Variables ASD (n=30) CONTROL (n=20) P value 
Age 9.0±0.33 9.1±1.4 0.976426 
Gender    
 Male 8.8±4.4 9.1±0.6 0.3 
 Female 9.4±0.5 9.0±0.7  0.92 
HTR1A expression Levels (normalized Copy numbers) 1950±395 6468±1037 0.0062 
Data are represented as mean±SEM 
 
DISCUSSION 
Zafeiriou et al. [6] suggested that in ASD, serotonin (5-HT) system 
have been disrupted. A variation in sequence in the serotonin genes 
is well-replicated leading to this disruption. Consequently, their 
involvement in the development of ASD has gained extensive studies 
[14]. The 5 HT1A receptors is considered as a molecular target for 
the action of serotonin [15]. In the current investigations, the gene 
expression levels of HTR1A gene were markedly reduced in ASD 
patients as compared to healthy controls. This finding is consistent 
with that of Sener et al., [11] who reported that the expression of 
HTR1A was undetectable in autistic Turkish children. 
In the central nervous system, the rate-determining enzyme 
tryptophan hydroxylase 2 (TPH2) are secreted by the brain 5-HT 
system and evolves from neurons of the raphe nuclei [16]. In non-
neuronal cells, the expression of 5-HT1A could be knocked down by 
a group of repressor elements in the upstream from the minimal 
promoter. Besides, in neuronal cell lines that express 5-HT1A 
receptors, the transcription of 5-HT1A could be down-regulated 
[17]. However, not all subcategories of neurons contain the 5-HT1A 
receptors, and consequently, more down regulators are needed to 
reduce its expression to exact neurons [18].  
In the prefrontal cortex (PC), the main cause of the suppression of 
neuronal output by 5-HT1A receptors is the hyperpolarizing 
potassium current acceleration. Meanwhile, the output is mediated by 
5-HT2A receptors through phospholipase induction [19]. Moreover, 
serotinin 1A receptor agonists were reported to mediate the release of 
dopamine in the PC. Besides, it can moderate the effect of dopamine 
D2 receptor blockers on the secretion of dopamine [20]. Diaz-Mataix et 
al. [21, 22] reported that dopaminergic neurons in the ventral 
tegmental area could be potentiated by activation of PFC 5-HT1A 
receptors, and also the mesocortical release is accelerated by it.  
The 5-HT1A autoreceptor signaling in raphe neurons was explored 
in previous work [23]. 5-HT1A was found to inhibit adenylyl cyclase 
activity, and hence negatively regulates serotonergic neuronal 
activity. The 5-HT1A autoreceptor chronic desensitization is needed 
to gain increased serotonergic neurotransmission [24] and to 
activate serotonin synthesis [25]. Building on this fact in humans, 
the 5-HT1A autoreceptors level is inversely associated with raphe 5-
HT formation in human [26].  
When 5-HT1A auto receptor expression is increased, the activity of 
5-HT neurons is suppressed. Meanwhile, an abolished behavioral 
response to 5-HT may be caused by suppressed post-synaptic 5-
HT1A receptors. Mental illness susceptibility is regulated by the 
receptor of 5-HT1A. However, further explorations for the exact 
pathway causing variable changes in the receptor of 5-HT1A are 
needed [10]. 
Increasing in 5-HT neuron firing rate and accelerated 5-HT output 
were recorded in Mice with a 30% suppression in 5-HT1A auto 
receptors [27]. Endogenous 5-HT1A receptors were expressed in 
some neuronal cell lines. Particularly, the rat raphe RN46A cells which 
express the receptors of 5-HT1A. These cells are serotonergic and 
could be utilized as a model for 5-HT1A auto receptor handling [28].  
CONCLUSION 
This study concluded that the HTR1A gene expressions were greatly 
reduced in samples of ASD. This finding could suggest the 
importance of enrolling this gene in further studies in order to 
determine its exact role in ASD etiology. 
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